Topline data from the SAD portion of the Phase 1 trial of KPL-387 support potential monthly SC dosing in recurrent ... Humira (adalimumab), or Remicade (infliximab), as this may increase your ...

Topline data from the SAD portion of the Phase 1 trial support potential monthly SC dosing in recurrent pericarditis ... Humira (adalimumab), or Remicade (infliximab), as this may increase ...

Methods: The infliximab dose of all patients with RA treated at our centre was decreased from 5 mg/kg to 3 mg/kg, leaving dosing intervals unaltered. Subsequently patients were followed for at least ...

Most patients (87%) did not develop ADAs during the study. Dosing of infliximab at week 48 compared to baseline was stable for 40% of patients, lower for 39% and higher for 21% of patients. The ...

Monotherapy may be offered to patients with scleritis and may be efficacious over the long term. In our experience, the optimal maintenance infliximab dosing interval for patients with scleritis is ...

TNF-α monoclonal antibodies (e.g. Infliximab and Adalimumab ... necessitating optimization of dosing schedules and therapeutic sequences to maximize efficacy while minimizing overlapping toxicities.

46 Third, the dose or dosing interval of efmarodocokin alfa may not be optimised ... one patient had concomitant treatment with infliximab and two others were treated with stable doses of vedolizumab.

Continued dosing through week 24 maintained or further improved the signs and symptoms of PsA and physical function. Results based on additional efficacy measures, including ACR50, ACR70, swollen and ...

Remicade (infliximab) is a prescription drug that’s used to treat certain autoimmune conditions. This drug can interact with certain vaccines and other medications, such as immunosuppressant ...

Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

The sales growth was partially dampened by lower sales of Stelara, Imbruvica and generic/biosimilar competition to drugs like Zytiga and Remicade.